epocrates, an athenahealth, Inc. company that delivers digital clinical decision support to prescribers, announced the expansion of its commercial leadership team to drive the enhancement and development of the company’s commercial product offerings and customer success model. The group recently brought on Andrew Johnson to serve as executive director, commercial strategy, and Bridget Seay to serve as executive director, customer experience & commercial consulting.
“Pharmaceutical marketers are currently under immense pressure to drive meaningful results in an increasingly competitive, digital landscape. In turn, they are looking for consultative services driven by best-in-class market intelligence to help them achieve campaign goals and enhance clinical engagement,” said Matt Titus, vice president, chief commercial officer, epocrates.
Johnson will oversee the epocrates sales team supporting the team leads and driving commercial execution for the business. With more than 15 years of sales and leadership experience, he moves to epocrates from athenahealth, where he was named the 2021 athenahealth Sales Leader of the Year and led the athenaPractice sales organization.
Seay will lead the solutions design and account management functions, as well as focusing on epocrates’ evolution to a customer success organization. An industry veteran of nearly 20 years, she joins epocrates from Wiley, a global leader in research and education, where she led strategic growth, development, and product lifecycle of the Corporate Partner Solutions advertising portfolio and its evolving Partner Solutions customer base.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.